Clinical trial

Autologous Platelet Gel in Wound Healing of Coronary Artery Bypass Grafting (CABG) Patients

Name

0065-08-FB

Description

This study will determine if autologous platelet gel (APG) on sternal incision and conduit sites will improve wound healing and decrease infection in coronary artery bypass grafting surgery patients.

Trial arms

Trial start

2009-01-13

Estimated PCD

2010-01-06

Trial end

2010-01-06

Status

Withdrawn

Treatment

autologous platelet gel

Patients will receive APG to the surgical site in the operating room. The control site will receive no treatment.

Arms:

Control (No platelet gel), Platelet Gel

Primary endpoint

Healing and infection of surgical sites

30 days

Eligibility criteria

Inclusion Criteria: * Any patient who meets criteria and consents to undergo a CABG procedure involving conduit sites and consents to this study. Exclusion Criteria: * Any patient, after inclusion, whom is later determined to have had on-going therapy that could influence wound healing such as radiation or chemotherapy, extensive steroid use, or accidental trauma such as burns, etc.

Protocol

{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 0, 'type': 'ACTUAL'}}

Updated at

2023-08-15

1 organization

1 product

2 indications

Organization

University of Nebraska

Product

Autologous Platelet Gel

Indication

Wound

Indication

Infection